Eli Lilly
LLY • NYSE
Eli Lilly is a drug manufacturers - general company in the healthcare sector trading on NYSE, led by CEO David A. Ricks, with a market cap of $952.34B.
CEODavid A. Ricks
Market Cap$952.34B
Drug Manufacturers - General
Healthcare
Employees43.0K
Websitelilly.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Eli Lilly
Date
Thursday, April 30, 2026 (in 2 months)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$7.28
Revenue Estimate
$17.5B
Earnings History
Past 12 earnings reports for Eli Lilly
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 4, 2026 | Q4 2025 | $7.54Est: $6.96 | +8.3% | $19.3BEst: $17.9B | +7.7% |  10-K |
| Oct 30, 2025 | Q3 2025 | $7.02Est: $5.96 | +17.8% | $17.6BEst: $16.0B | +9.7% | 10-Q |
| Aug 7, 2025 | Q2 2025 | $6.31Est: $5.60 | +12.7% | $15.6BEst: $14.7B | +5.8% | 10-Q |
| May 1, 2025 | Q1 2025 | $3.34Est: $3.02 | +10.6% | $12.7BEst: $12.7B | +0.5% | 10-Q |
| Feb 6, 2025 | Q4 2024 | $5.32Est: $5.08 | +4.7% | $13.5BEst: $13.4B | +0.8% | 10-K |
| Oct 30, 2024 | Q3 2024 | $1.18Est: $1.45 | -18.6% | $11.4BEst: $12.1B | -5.5% | 10-Q |
| Aug 8, 2024 | Q2 2024 | $3.92Est: $2.70 | +45.2% | $11.3BEst: $10.0B | +13.6% | 10-Q |
| Apr 30, 2024 | Q1 2024 | $2.58Est: $2.46 | +4.9% | $8.8BEst: $8.9B | -1.7% | 10-Q |
| Feb 6, 2024 | Q4 2023 | $2.49Est: $2.19 | +13.7% | $9.4BEst: $8.9B | +4.7% | 10-K |
| Nov 2, 2023 | Q3 2023 | $0.10Est: -$0.15 | +166.7% | $9.5BEst: $9.0B | +6.1% | — |
| Aug 8, 2023 | Q2 2023 | $2.11Est: $1.99 | +6.0% | $8.3BEst: $7.6B | +9.7% | 10-Q |
| Apr 27, 2023 | Q1 2023 | $1.62Est: $1.73 | -6.4% | $7.0BEst: $6.9B | +1.5% | — |